• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Alexion To Lay Off Staff And Refocus Strategy

    Bryan Mc Govern
    Mar. 15, 2017 12:04PM PST
    Pharmaceutical Investing
    Pharmaceutical Investing

    Alexion Pharmaceuticals will layoff 200 people as it begins a focus shift for the company.

    Alexion Pharmaceuticals (NASDAQ:ALXN) a rare disease drug developer will cut down on its research and development (R&D) programs and lay off 200 people. The company had recently reported a positive 2016, stating a $3.084 billion in total revenue.
    Interim CEO David Brennan said in their financial report for last year to “prepare for the potential launches of Soliris in refractory gMG, and focus on our highest priority R&D programs.”
    Brennan will also assume the role of chairman of the board after it was announced Dr. Leonard Bell, who founded Alexion Pharmaceuticals will retire in May of this year.

    Recent Changes in the Company

    Alexion told Reuters in a statement they were investing in key growth drivers, including their portfolio of marketed products.
    Last year CEO David Hallal and CFO Vikas Sinha stepped down from their positions amid allegations of improper sales practices.
    The company’s lead product Soliris was the source of most growth in the company, however, its sales have recently slowed down.
    The company has yet to announce where exactly the cuts will be made and what programs will suffer the most based on this development. Alexion is expected to provide a company update on their upcoming Q1 financial results. In a year Alexion’s share price has gone down 8.87 percent.


    FierceBiotech reported on Barclays analyst Dr. Geoff Meacham saying the changes were “planned and incorporated” based on their fourth quarter earnings call last year.
    The FDA will review the potential for Soliris to treat patients with refractory generalized myasthenia gravis, a rare chronic disease.

    Alexion’s Stock Performance

    Alexion hopes to find a new market for Soliris to gain the revenue it had recently lost. However, Alexion has now failed a couple of tests for Soliris. Alexion’s stock price as of 12:00 PST is 122.44.
    Don’t forget to follow us @INN_LifeScience for real-time news updates!
    Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

    pharmaceutical investingr&dcompany updatealexion pharmaceuticalsfinancial resultsrare disease
    The Conversation (0)

    Go Deeper

    AI Powered
    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×